NCT02653547

Brief Summary

Patients receive two weeks of treatment (prefrontal high-frequency and bilateral low-frequency rTMS vs. prefrontal high-frequency and bilateral high-frequency rTMS). After two weeks of treatment they can decide if they want to quit the treatment or if they want to proceed with the treatment for another two weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

January 8, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 12, 2016

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 23, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 23, 2018

Completed
Last Updated

June 18, 2018

Status Verified

June 1, 2018

Enrollment Period

2.4 years

First QC Date

January 8, 2016

Last Update Submit

June 14, 2018

Conditions

Keywords

tinnitustranscranial random noise stimulationrTMSmultisite stimulationnon-invasive brain stimulation

Outcome Measures

Primary Outcomes (1)

  • change in tinnitus questionnaire

    change in tinnitus questionnaire

    week12

Secondary Outcomes (6)

  • change in tinnitus questionnaire

    week2, week3, week4, week12

  • change in tinnitus handicap inventory

    week2, week3, week4, week12

  • change in tinnitus numeric rating scales

    week2, week3, week4, week12

  • change in major depression inventory

    week2, week3, week4, week12

  • change in clinical global impression

    week2, week3, week4, week12

  • +1 more secondary outcomes

Study Arms (4)

standard multisite four weeks

EXPERIMENTAL

Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks

Other: standard multisite four weeks

high-frequency multisite four weeks

EXPERIMENTAL

Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks

Other: high-frequency multisite four weeks

standard multisite two weeks

EXPERIMENTAL

Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks

Other: standard multisite two weeks

high-frequency multisite two weeks

EXPERIMENTAL

Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks

Other: high-frequency multisite two weeks

Interventions

Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).

standard multisite four weeks

Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).

high-frequency multisite four weeks

Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).

standard multisite two weeks

Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).

high-frequency multisite two weeks

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • written informed consent
  • duration of tinnitus more than 6 months
  • bothersome chronic tinnitus

You may not qualify if:

  • not stable internal, mental, and neurological diseases
  • contraindication for rTMS (pacemaker, metal implants, pregnancy, epilepsy, status post severe craniocerebral injury )
  • uninvolvement in other treatment studies for tinnitus at the same time

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Regensburg- Dept of Psychiatry

Regensburg, 93053, Germany

Location

MeSH Terms

Conditions

Tinnitus

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Berthold Langguth

    University of Regensburg, Department of Psychiatry

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D., Ph.D.

Study Record Dates

First Submitted

January 8, 2016

First Posted

January 12, 2016

Study Start

January 1, 2016

Primary Completion

May 23, 2018

Study Completion

May 23, 2018

Last Updated

June 18, 2018

Record last verified: 2018-06

Locations